OncoMatch/Clinical Trials/NCT03391778
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Is NCT03391778 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ADP adoptive cell therapy for neoplasms.
Treatment: ADP adoptive cell therapy — This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: adoptive cell therapy (ADP adoptive cell therapy agent, GSK adoptive cell therapy)
Participants who have received at least one dose of ADP adoptive cell therapy agent; Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University School of Medicine · Atlanta, Georgia
- ADP Investigational Site · Baltimore, Maryland
- National Cancer Institute - Center for Cancer Research · Bethesda, Maryland
- University of Michigan · Ann Arbor, Michigan
- Washington University School of Medicine in St. Louis · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify